KV Targets Citigroup Over $72M In Illiquid ARS
KV Pharmaceutical Co. has targeted Citigroup Global Markets Inc. with a suit that accuses the bank of inducing the drug manufacturer to invest in auction rate securities and leaving it in...To view the full article, register now.
Already a subscriber? Click here to view full article